BMS chooses interim finance chief as permanent CFO

Bristol-Myers Squibb now has a permanent CFO, but he's not new. It's Charles Bancroft, who's been doing the job on an interim basis since the beginning of the year. Bancroft now bears the official CFO title, and he'll report to Lamberto Andreotti (photo), the current COO who takes over as chief executive next month. He replaces Jean-Marc Huet (photo), who left BMS in December.

Bancroft joined BMS in 1984, and he's been moving up the finance side ever since. He's served the company overseas and taken on senior jobs in its global pharma business and at ConvaTec, the wound care unit sold off in 2008. Most recently, he was VP of finance for the pharma unit. He's a CPA with an MBA from Temple University.

BMS is just the latest Big Pharma to name a new CFO. Over the last several years, new execs have taken the finance reins at Pfizer, Sanofi-Aventis, Novartis and AstraZeneca. 

- see the release from BMS
- read the Reuters story
- get more from RTT News

Related Articles:
BMS' Cornelius to retire, Andreotti named CEO
Is Lilly CFO's promotion a succession plan?

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.